Prelude Therapeutics To Engage In Hematology And Oncology Summit
Prelude Therapeutics to join Citizens JMP Securities Hematology & Oncology Summit on Dec 2, featuring a fireside chat with its leadership.
Prelude Therapeutics Incorporated is a clinical-stage company specialising in precision oncology. It announced its participation in the upcoming Citizens JMP Securities Hematology and Oncology Summit today. The virtual event is scheduled for December 2, 2024.
On Monday, December 2, at 11:30 a.m. ET, Prelude’s Chief Executive Officer, Kris Vaddi, Ph.D., and President and Chief Medical Officer, Jane Huang, M.D., will participate in a fireside chat.
The live webcast of the discussion will be accessible through the Events and Presentations section of the company’s website. For convenience, a session recording will be archived and available for viewing on the site for 90 days.
Simantini Singh Deo works on the latest and trending news happening daily in the pharma world.
Plus dans Pharma News
Tous les articles →
Medicus Pharma soumet à la FDA le protocole de Phase 2b/3 pour Teverelix
Fresenius Kabi reçoit une lettre d’avertissement de la FDA après des défaillances d’enquête sur le traitement aseptique dans l’établissement de Melrose Park
Discussion